SequelSEC

DataMeds AI, Inc. MEDS

Wholesale-Drugs, Proprietaries & Druggists' Sundries · CIK 0002030763 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$8.02M
Fiscal year ended 2026-06-30
Operating income
-$70.26M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$27.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.26Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Wholesale-Drugs, Proprietaries & Druggists' Sundries filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin-27.5%0th
Net margin-433.9%0th
Operating margin-401.7%0th
Revenue YoY growth28.7%100th
SBC / revenue234.8%100th
Current ratio0.09x12th

DataMeds AI, Inc. (MEDS) reported revenue of $8.02M and net income of -$88.28M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from DataMeds AI, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Wholesale-Drugs, Proprietaries & Druggists' Sundries.

Income

DataMeds AI, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$8.02M
Cost of revenue$15.30M
Gross profit-$7.27M
Operating income-$70.26M
Net income-$88.28M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax income-$88.28M
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$48.12M
General & administrative$46.23M
Selling & marketing$1.89M

Balance

DataMeds AI, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$2.46M
Total assets$32.76M
Current assets$5.63M
Total liabilities$52.26M
Current liabilities$39.41M
Total equity incl. NCI-$19.50M
Temporary (mezzanine) equityUnavailable
Inventory$1.51M
Accounts receivable$1.17M
Goodwill$14.19M
Long-term debt$12.60M
Accounts payableUnavailable

Cash flow

DataMeds AI, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$13.74M
Capital expendituresUnavailable
Investing cash flow-$923.70K
Financing cash flow$16.70M
Net change in cash$2.04M
Stock-based compensation$28.65M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.32M

Derived

DataMeds AI, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin-90.6%
Operating margin-875.7%
FCF marginUnavailable
SBC / revenue357.1%
Current ratio0.14x
Revenue YoY growth-78.2%
Net margin-1100.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MEDS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-17View SEC filing
10-Q · Filed 2026-05-19View SEC filing
10-K · Filed 2026-03-20View SEC filing
10-Q · Filed 2025-11-19View SEC filing
10-Q · Filed 2025-08-19View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

CAH COR COSM HLF HWH MCK NUS STEK

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.